Pete O'Heeron - 04 May 2026 Form 4 Insider Report for FibroBiologics, Inc. (FBLG)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: FBLG
Reported as of: 04 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 May 2026, 19:01:11 UTC
Prior SEC filing: 04 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Ruben A. Garcia, by Power of Attorney

Key filing fact

Pete O'Heeron filed Form 4 for FibroBiologics, Inc. (FBLG) on 04 May 2026.

Key facts

This page summarizes Pete O'Heeron's Form 4 filing for FibroBiologics, Inc. (FBLG).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 May 2026, 19:01.

Change

Previous filing in this sequence was filed on 04 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001569334 Primary reporting owner

O'HEERON PETE

Relationship: CHIEF EXECUTIVE OFFICER, Director
Address: C/O FIBROBIOLOGICS, INC., 9350 KIRBY DRIVE, SUITE 300, HOUSTON
Signature: /s/ Ruben A. Garcia, by Power of Attorney
Signature date: 04 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FBLG transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +92,410
Change %
Price: $0.000000^*
Shares after: 92,410
Date: 04 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 92,410
Exercise price: $1.38
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On May 4, 2026, the reporting person was granted an option to purchase 92,410 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.